- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03458026
Move Your Spondyl " Better Live Its Rheumatism With the Physical Activity "
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Christian ROUX, Pr
- Phone Number: 04 92 03 54 91
- Email: roux.c2@chu-nice.fr
Study Contact Backup
- Name: Sabia ACHIOU
- Phone Number: 04 92 03 54 91
- Email: achiou.s@chu-nice.fr
Study Locations
-
-
-
Nice, France, 06003
- CHU de Nice
-
Contact:
- Christian ROUX, Pr
- Phone Number: 04 92 03 54 91
- Email: roux.c2@chu-nice.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Presenting a spondyloarthritis according to the criteria of the ASAS (l'Assessment of SpondyloArthritis international Society)
- Benefiting from a stable treatment by biotherapies for at least 3 months
Exclusion Criteria:
- Patient presenting a cardiac pathology should be decompensating
- Patients having a contraindication in the physical activity
- Lung affection making impossible the effort
- Patient already realizing a physical activity supervised in club or with sports coach
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: connected object + SMS of physical activity reminders
The patients will be included during their visit of follow-up and will receive a watch connected. They will have an information meeting for their to explain how step shows it. They will also receive advice to practise an adapted physical activity. During 12 weeks of SMS (text messages) every week to motivate them to realize these exercises. At the end of 12 weeks the connected watch will be deprived of them as well as SMS (text messages). They will have to realize an activity in autonomy during 12 weeks. At the end of the twenty-fourth week, they will get back their watch. They will have in more 1 session with a coach and 2 sessions to be made in autonomy during 12 weeks. In 36 week, they return the watch and finish the study. |
Watch connected used and receipt of SMS (text messages)
|
Other: Without connected object
The patients will be included during their visit of follow-up.They will have an information to practice suitable activity during 12 weeks At the end of 12 weeks, they realised follow-up. They will have to realize an activity in autonomy during 12 weeks. At the end of the twenty-fourth week, they will have 1 session with a coach and 2 sessions to be made in autonomy during 12 weeks. In 36 week, the study will be finished. |
Any intervention except follow-up visit
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of pushes brought reported by the patient through a filled auto-questionnaire every week
Time Frame: After 12 weeks
|
This questionnaire containing 3 items: did you present a push of your disease since the last filling of the questionnaire?,not, yes during 1 in 3 in the daytime,yes more than 3 days
|
After 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Moderators of the membership will be estimated thanks to the EMAPS (Scale of Motivation for Physical activity for health purposes) and thanks to the Big five
Time Frame: 12 weeks
|
the EMAPS questionnaire will allow to quantify by the motivation of the patients to practice a physical activity. this questionnaire is specifically for health purposes. |
12 weeks
|
The level of commitment in the physical activity will be estimated by the questionnaire GPAQ (Global Physical Activity Questionnaire)
Time Frame: 12 weeks
|
the qestionnaire GPAQ is a scale to quantify overall physical activity (based on physical activity at work and in the home).
|
12 weeks
|
The function will be estimated by the BASFI (Bath Ankylosing Spondylitis Fonctional Index)
Time Frame: 12 weeks
|
12 weeks
|
|
The activity of the disease will be estimated by the BASDAI (Bath Ankylosing Spondylitis Disease Activity Index)
Time Frame: 12 weeks
|
12 weeks
|
|
The activity of the disease will be estimated by the BASFI (Bath Ankylosing Spondylitis Fonctional Index)
Time Frame: 12 weeks
|
12 weeks
|
|
The activity of the disease will be estimated by the ASQOL (Ankylosing Spondylitis Quality of Life Questionnaire)
Time Frame: 12 weeks
|
the ASQOL questionnaire is a quality of life scale.
this questionnaire is specifically designed for patients with spondyloarthritis.
|
12 weeks
|
The activity of the disease will be estimated by the BASDAI (Bath Ankylosing Spondylitis Disease Activity Index)
Time Frame: 24 weeks
|
24 weeks
|
|
The activity of the disease will be estimated by the BASFI (Bath Ankylosing Spondylitis Fonctional Index)
Time Frame: 24 weeks
|
24 weeks
|
|
The activity of the disease will be estimated by the ASQOL (Ankylosing Spondylitis Quality of Life Questionnaire)
Time Frame: 24 weeks
|
the ASQOL questionnaire is a quality of life scale.
this questionnaire is specifically designed for patients with spondyloarthritis.
|
24 weeks
|
The activity of the disease will be estimated by the BASDAI (Bath Ankylosing Spondylitis Disease Activity Index)
Time Frame: 36 weeks
|
36 weeks
|
|
The activity of the disease will be estimated by the BASFI (Bath Ankylosing Spondylitis Fonctional Index)
Time Frame: 36 weeks
|
36 weeks
|
|
The activity of the disease will be estimated by the ASQOL (Ankylosing Spondylitis Quality of Life Questionnaire)
Time Frame: 36 weeks
|
the ASQOL questionnaire is a quality of life scale.
this questionnaire is specifically designed for patients with spondyloarthritis.
|
36 weeks
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Saraux A, Guillemin F, Guggenbuhl P, Roux CH, Fardellone P, Le Bihan E, Cantagrel A, Chary-Valckenaere I, Euller-Ziegler L, Flipo RM, Juvin R, Behier JM, Fautrel B, Masson C, Coste J. Prevalence of spondyloarthropathies in France: 2001. Ann Rheum Dis. 2005 Oct;64(10):1431-5. doi: 10.1136/ard.2004.029207. Epub 2005 Apr 7.
- Passalent LA, Soever LJ, O'Shea FD, Inman RD. Exercise in ankylosing spondylitis: discrepancies between recommendations and reality. J Rheumatol. 2010 Apr;37(4):835-41. doi: 10.3899/jrheum.090655. Epub 2010 Mar 1.
- Fongen C, Sveaas SH, Dagfinrud H. Barriers and Facilitators for Being Physically Active in Patients with Ankylosing Spondylitis: A Cross-sectional Comparative Study. Musculoskeletal Care. 2015 Jun;13(2):76-83. doi: 10.1002/msc.1088. Epub 2014 Nov 5.
- O'Dwyer T, McGowan E, O'Shea F, Wilson F. Physical Activity and Exercise: Perspectives of Adults With Ankylosing Spondylitis. J Phys Act Health. 2016 May;13(5):504-13. doi: 10.1123/jpah.2015-0435. Epub 2015 Oct 28.
- Labat G, Hayotte M, Bailly L, Fabre R, Brocq O, Gerus P, Breuil V, Fournier-Mehouas M, Zory R, D'Arripe-Longueville F, Roux CH. Impact of a Wearable Activity Tracker on Disease Flares in Spondyloarthritis: A Randomized Controlled Trial. J Rheumatol. 2022 Oct;49(10):1109-1116. doi: 10.3899/jrheum.220140. Epub 2022 Jun 15.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17-PP-12
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spondyloarthritis
-
UCB Biopharma SRLCompletedNonradiographic Axial SpondyloarthritisUnited States, Belgium, Bulgaria, China, Czechia, France, Germany, Hungary, Japan, Poland, Spain, Turkey, United Kingdom
-
Novartis PharmaceuticalsRecruitingNon-radiographic Axial SpondyloarthritisBelgium, Netherlands, Italy, Thailand, Hungary, Malaysia, Germany, Israel, France, Czechia, Colombia, Romania, Poland, Turkey, Vietnam, Brazil, Mexico, Philippines
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...Not yet recruitingAxial SpondyloarthritisChina
-
Merck Sharp & Dohme LLCCompletedSpondyloarthritisCzechia, Germany, Netherlands, Poland, Romania, Russian Federation, Spain, Turkey, Ukraine
-
Novartis PharmaceuticalsActive, not recruitingNon-radiographic Axial SpondyloarthritisChina
-
UCB Biopharma SRLActive, not recruitingAnkylosing Spondylitis | Axial Spondyloarthritis | r-axSpa | Nr-axSpaUnited States, Belgium, Bulgaria, China, Czechia, France, Germany, Hungary, Japan, Netherlands, Poland, Spain, Turkey, United Kingdom
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...Healthcare PharmaceuticalsRecruitingSpondyloarthritis, AxialBangladesh
-
Fondazione Policlinico Universitario Agostino Gemelli...Not yet recruitingSpondyloarthritis | Spondyloarthritis, AxialItaly
-
UCB BIOSCIENCES GmbHCompletedAxial Spondyloarthritis | Nonradiographic Axial Spondyloarthritis | Nr-axSpAUnited States, Australia, Bulgaria, Canada, Czechia, Hungary, Poland, Russian Federation, Taiwan
-
Centre Hospitalier Universitaire de BesanconNot yet recruitingSpondyloarthritis, AxialFrance
Clinical Trials on Connected object use combined with SMS (text messages) of physical activity reminders
-
University of California, San DiegoCarol Vassiliadis FamilyCompletedObesity | Health BehaviorUnited States